ArticleNature cancer2023
CD8
Open access · hybridAbstract read
In one paragraph
Article in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 1 pooled it
21.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects.Frontiers in immunology · 2024Pooled it
- Harnessing the NKG2D immune surveillance pathway using engineered T-cells for the treatment of human disease.Human vaccines & immunotherapeutics · 2026Review
- The protein kinase IKK epsilon shapes the melanoma tumor microenvironment by modulating angiogenesis and the T-cell immunity.Molecular medicine (Cambridge, Mass.) · 2026Article
- Re-expression of MHC-I to treat CNS cancers.Oncotarget · 2026Review
- Pre-Regenerative Endothelial Cells Empowered by Antler Blood Exosomes Orchestrate Peripheral Nerve Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting colorectal cancer and T‑cell metabolism for the treatment of colorectal cancer (Review).Oncology reports · 2026Review
- Article
- Targeting the NKG2D axis in head and neck squamous cell carcinoma: from molecular insights to clinical applications.Cancer cell international · 2026Review
- Immunoinformatics-driven design of a multi-epitope vaccine against Seoul Virus: Structural, dynamic, and immunogenic profiling.Clinics (Sao Paulo, Brazil) · 2026Article
- Intratumoral TScience immunology · 2026Article
- Targeting SLC5A2 suppresses colorectal tumour development by enhancing NK cell activity through extracellular vesicle-dependent MICA/B signalling.Clinical and translational medicine · 2026Article
- An Immunomodulating Peptide With Potential to Counteract Endometriosis.The Australian & New Zealand journal of obstetrics & gynaecology · 2026Article
- Cationic mRNA Lipid Nanoparticles for Ex Vivo NanoCAR-T Cell Engineering.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Disrupting USP14-mediated PARP1 dynamics reinstates MIC-A/B-driven antigen-independent CD8Science advances · 2026Article
- IL-18-Mediated Tumor Immune Evasion.Current issues in molecular biology · 2026Review
- Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16-CXCR6 signaling for potent antitumor response.Nature communications · 2026Article
- Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Tumor Microenvironments in Malignant Ovarian Germ Cell Tumors: MHC Class I Loss and T-Cell Exhaustion in Dysgerminoma.Cancer science · 2026Article
- Systemic activation and tissue infiltration of CD8 + CX3CR1 + T cells in non-small cell lung cancer treated with neoadjuvant immune checkpoint blockade.British journal of cancer · 2026Article
- Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study.Cancer immunology, immunotherapy : CII · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byCD82023
Authors and funding
19 authors at 2 institutions in 1 country.
Emily C Lerner *Duke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0003-1597-8581
Karolina I Woroniecka *Department of Pathology, Duke University Medical Center, Durham, NC, USA.
Vincent M D'AnniballeDuke University School of Medicine, Durham, NC, USA.
Daniel S WilkinsonPreston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Aditya A MohanDepartment of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Selena J LorreyDepartment of Immunology, Duke University Medical Center, Durham, NC, USA.
Jessica Waibl-PolaniaDepartment of Pathology, Duke University Medical Center, Durham, NC, USA.
Lucas P WachsmuthDuke University School of Medicine, Durham, NC, USA.
Alexandra M MiggelbrinkDepartment of Pathology, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0003-1499-2269
Joshua D JacksonDepartment of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Xiuyu CuiDepartment of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Jude A RajDuke University School of Medicine, Durham, NC, USA.
William H TomaszewskiDepartment of Immunology, Duke University Medical Center, Durham, NC, USA.
Sarah L CookPreston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0002-0516-9388
John H SampsonPreston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0002-0104-7658
Anoop P PatelPreston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0001-7078-9535
Mustafa KhasrawPreston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0003-3249-9849
Michael D GunnDepartment of Immunology, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0003-4602-0667
Peter E FecciPreston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA. peter.fecci@duke.edu.ORCID http://orcid.org/0000-0002-2912-8695
Duke Medical Center · USDuke University · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MTargeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 AntibodyP50CA190991 · NCI · DUKE UNIVERSITY · PI ALI-OSMAN, FRANCIS, ASHLEY, DAVID M. · 2014 to 2023
$20.8MBasic Immunology Training ProgramT32AI052077 · NIAID · DUKE UNIVERSITY · PI KRANGEL, MICHAEL S · 2002 to 2024
$4.2MNINDS Research Education Programs for Residents and Fellows in NeurosurgeryR25NS065731 · NINDS · DUKE UNIVERSITY · PI FECCI, PETER, HASAN, DAVID M. · 2009 to 2023
$968kNINDS Research Education Programs for Residents and Fellows in NeurosurgeryUE5NS065731 · NINDS · DUKE UNIVERSITY · PI FECCI, PETER, HASAN, DAVID M. · 2024 to 2024
$0kNCI NIH HHS P50 CA190991NIAID NIH HHS T32 AI052077NIGMS NIH HHS T32 GM007171NINDS NIH HHS R25 NS065731NINDS NIH HHS UE5 NS065731
Abstract
The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8
Indexed as
CD8-Positive T-LymphocytesNeoplasmsAnimalsAntigensHistocompatibility Antigens Class IHumansMiceNK Cell Lectin-Like Receptor Subfamily KAntigensHistocompatibility Antigens Class IKlrk1 protein, mouseNK Cell Lectin-Like Receptor Subfamily K
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.